Tan Tock Seng Hospital | Clinical Research and Innovation Office

Research site

(Unclaimed)

Location

16 Jalan Tan Tock Seng, Singapore, Central Singapore, Singapore

Site insights

Top conditions

Top treatments

Bevacizumab

Upadacitinib

ABT-494

Atezolizumab

BI 1015550

Pembrolizumab

Meropenem

Nivolumab

Filgotinib

Selpercatinib

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

49 of 247 total trials

Locations recently updated

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast (FIBRONEER™-ON)

This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have c...

Enrolling

Progressive Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

Drug: Nerandomilast

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 (U-ENDURE)

A multicenter study to evaluate the efficacy and safety of maintenance and long-term treatment administration of upadacitinib, an orally administered...

Active, not recruiting

Crohn's Disease

Drug: Placebo for Upadacitinib

Drug: Upadacitinib

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called Fosmanogepix) for the potential treatment o...

Enrolling

Candidemia

Candidiasis, Invasive

Drug: Fluconazole

Drug: Fosmanogepix

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation (HERMES)

This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get z...

Enrolling

Heart Failure

Drug: Placebo

Drug: Ziltivekimab

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

A study designed tocompare progression-free survival (PFS) in participants with t(11;14)-positive MM treated with venetoclax in combination with dexa...

Active, not recruiting

Multiple Myeloma

Drug: Pomalidomide

Drug: Venetoclax

A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152) (SKYSCRAPER-14)

The purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in combination wi...

Active, not recruiting

Hepatocellular Carcinoma

Other: Placebo

Drug: Bevacizumab

Locations recently updated

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum d...

Enrolling

Non-Small Cell Lung Cancer (NSCLC)

Drug: Sotorasib

Drug: Pembrolizumab

Status recently updated

A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) (HORIZON 1)

This study will evaluate the efficacy and safety of multiple therapies in participants with locally advanced, unresectable, Stage III NSCLC with elig...

Enrolling

Active, not recruiting

Non-Small Cell Lung Cancer

Drug: Durvalumab

Drug: Entrectinib

A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation (IMbrave050)

This study will evaluate the efficacy and safety of adjuvant therapy with atezolizumab plus bevacizumab compared with active surveillance in particip...

Active, not recruiting

Carcinoma, Hepatocellular

Drug: Bevacizumab

Drug: Atezolizumab

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD)

The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.

Active, not recruiting

Crohn's Disease

Biological: JNJ-78934804

Biological: Golimumab

Locations recently updated

A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition

Immunoglobulin A nephropathy (IgAN) is a kidney condition. It happens when the body's immune system creates groups of proteins (called immune complex...

Enrolling

Kidney Disease

Drug: Mezagitamab

Drug: Placebo

A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431)

The reason for this study is to see if the study drug selpercatinib compared to a standard treatment is effective and safe in participants with rearr...

Active, not recruiting

Non-Small Cell Lung Cancer

Drug: Cisplatin

Drug: Selpercatinib

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (LIBRETTO-432)

The reason for this study is to see if the study drug, selpercatinib, compared to placebo is effective and safe in delaying cancer return in particip...

Active, not recruiting

Carcinoma, Non-Small-Cell Lung

Drug: Placebo

Drug: Selpercatinib

Locations recently updated

A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

Study WR42221 is a Phase IIIb, global, multicenter, randomized, visual assessor-masked study designed to assess the efficacy, safety, and pharmacokin...

Active, not recruiting

Neovascular Age-related Macular Degeneration (nAMD)

Device: Port Delivery System with Ranibizumab

Drug: Ranibizumab

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. (SYMPHONY-1)

The participants of this study would have relapsed/refractory follicular lymphoma.Follicular lymphoma is a type of blood cancer. It is referred to as...

Enrolling

Relapsed/Refractory Follicular Lymphoma

Follicular Lymphoma

Combination Product: Rituximab

Drug: Placebo oral tablet

Locations recently updated

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma (OLYMPIA-3)

This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy. The study...

Active, not recruiting

Diffuse Large B-cell Lymphoma (DLBCL)

Drug: Cyclophosphamide

Drug: Odronextamab

A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (CONSTANCE)

This study is a Phase IIIb/IV, multicenter, randomized, two-arm, open-label 100-week study to investigate the efficacy, safety, and durability of int...

Active, not recruiting

Neovascular Age-related Macular Degeneration (nAMD)

Drug: Faricimab

A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia (POYANG)

This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled study evaluating the efficacy and safety of faricimab in pa...

Active, not recruiting

Choroidal Neovascularization Secondary to Pathologic Myopia

Procedure: Sham Procedure

Drug: Faricimab

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer (INAVO122)

This study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcuta...

Enrolling

Metastatic Breast Cancer

Drug: Inavolisib

Drug: Optional Endocrine Therapy of Investigator's Choice

A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression (IMAGINATION)

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of sefaxersen (RO7434656), a novel Antisense Oligonucleotide (ASO...

Enrolling

Primary IgA Nephropathy

Drug: Placebo

Drug: Sefaxersen (RO7434656)